Prediction of health-related quality-of-life results after lung stereotactic body radiotherapy using dose-volume parameters from functional mapping on Gallium-68 perfusion PET/CT.

IF 3.3 2区 医学 Q2 ONCOLOGY
François Lucia, Jacques Lamour, Margaux Geier, Vincent Bourbonne, Fanny Pinot, Malik Nebbache, Frédérique Blanc-Béguin, Simon Hennebicq, Maëlle Mauguen, Kevin Kerleguer, Ulrike Schick, Olivier Pradier, Grégoire Le Gal, Pierre-Yves Salaun, David Bourhis, Pierre-Yves Le Roux
{"title":"Prediction of health-related quality-of-life results after lung stereotactic body radiotherapy using dose-volume parameters from functional mapping on Gallium-68 perfusion PET/CT.","authors":"François Lucia, Jacques Lamour, Margaux Geier, Vincent Bourbonne, Fanny Pinot, Malik Nebbache, Frédérique Blanc-Béguin, Simon Hennebicq, Maëlle Mauguen, Kevin Kerleguer, Ulrike Schick, Olivier Pradier, Grégoire Le Gal, Pierre-Yves Salaun, David Bourhis, Pierre-Yves Le Roux","doi":"10.1186/s13014-025-02685-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The PEGASUS trial was the first study to evaluate and demonstrate the benefits of <sup>68</sup>Ga-perfusion PET/CT in the lung stereotactic body radiotherapy (SBRT) planning process in preserving functional lung volumes while respecting target volume coverage and doses to other organs at risk. Here we report the prespecified exploratory endpoint of SBRT on health-related quality of life (HRQoL).</p><p><strong>Methods: </strong>In this single-center prospective study, we recruited patients planned to be treated in our radiotherapy department with SBRT for primary or secondary lung tumors. Patient-reported outcomes were assessed at the first visit, 1 month, 3 months and every 3 months until 12 months after SBRT using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30), the EORTC Quality of Life Questionnaire Lung Cancer 13 items (QLQ-LC13), and the European Quality of Life 5 Dimensions-5 Level (EQ-5D-5 L) questionnaire. The key exploratory HRQoL endpoints (analyzed for all patients who completed at least QLQ-C30 at least one time point after SBRT) were baseline-to-early change (between 1 month and 3 month) and baseline-to-late change (between 6 month and 12 month) in the QLQ-C30 global health status (GHS)/quality-of-life (QoL) score and in the deterioration of the dyspnea (patient-reported lung toxicity). Explorative analysis of the impact of baseline HRQoL, patient- and SBRT-related characteristics, including PET perfusion-based functional parameters, on the change in HRQoL from baseline was analyzed using univariate analysis.</p><p><strong>Results: </strong>Of the 60 patients included, 39 were analyzable as early-onset and 22 as late-onset. Thirteen (33%) and 7 (32%) patients had a deterioration of QoL. In univariate analysis, maximal dose to the heart, doses to the functional lung volume and pulmonary functional test parameters were significantly associated with the early deterioration of HRQoL. Only doses to the functional lung volume were significantly associated with the late deterioration of HRQoL.</p><p><strong>Conclusion: </strong>In our study, increased radiation doses in functional lung volume PET bases dose parameters were significantly associated with a decrease of HRQoL unlike anatomic lung parameters. Functional lung avoidance planning guided by perfusion PET/CT may be a simple and noninvasive method to improve HRQoL in patients treated with lung SBRT.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"108"},"PeriodicalIF":3.3000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243402/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13014-025-02685-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The PEGASUS trial was the first study to evaluate and demonstrate the benefits of 68Ga-perfusion PET/CT in the lung stereotactic body radiotherapy (SBRT) planning process in preserving functional lung volumes while respecting target volume coverage and doses to other organs at risk. Here we report the prespecified exploratory endpoint of SBRT on health-related quality of life (HRQoL).

Methods: In this single-center prospective study, we recruited patients planned to be treated in our radiotherapy department with SBRT for primary or secondary lung tumors. Patient-reported outcomes were assessed at the first visit, 1 month, 3 months and every 3 months until 12 months after SBRT using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30), the EORTC Quality of Life Questionnaire Lung Cancer 13 items (QLQ-LC13), and the European Quality of Life 5 Dimensions-5 Level (EQ-5D-5 L) questionnaire. The key exploratory HRQoL endpoints (analyzed for all patients who completed at least QLQ-C30 at least one time point after SBRT) were baseline-to-early change (between 1 month and 3 month) and baseline-to-late change (between 6 month and 12 month) in the QLQ-C30 global health status (GHS)/quality-of-life (QoL) score and in the deterioration of the dyspnea (patient-reported lung toxicity). Explorative analysis of the impact of baseline HRQoL, patient- and SBRT-related characteristics, including PET perfusion-based functional parameters, on the change in HRQoL from baseline was analyzed using univariate analysis.

Results: Of the 60 patients included, 39 were analyzable as early-onset and 22 as late-onset. Thirteen (33%) and 7 (32%) patients had a deterioration of QoL. In univariate analysis, maximal dose to the heart, doses to the functional lung volume and pulmonary functional test parameters were significantly associated with the early deterioration of HRQoL. Only doses to the functional lung volume were significantly associated with the late deterioration of HRQoL.

Conclusion: In our study, increased radiation doses in functional lung volume PET bases dose parameters were significantly associated with a decrease of HRQoL unlike anatomic lung parameters. Functional lung avoidance planning guided by perfusion PET/CT may be a simple and noninvasive method to improve HRQoL in patients treated with lung SBRT.

Abstract Image

Abstract Image

利用镓-68灌注PET/CT功能定位的剂量-体积参数预测肺立体定向放射治疗后健康相关生活质量结果
PEGASUS试验是首个评估和证明68ga灌注PET/CT在肺立体定向放射治疗(SBRT)计划过程中保留功能肺体积,同时尊重靶体积覆盖范围和其他危险器官剂量的益处的研究。在这里,我们报告了SBRT对健康相关生活质量(HRQoL)的预先指定的探索性终点。方法:在这项单中心前瞻性研究中,我们招募了计划在我放射科接受SBRT治疗的原发性或继发性肺肿瘤患者。采用欧洲癌症研究与治疗组织(EORTC)生活质量问卷核心30项(QLQ-C30)、EORTC肺癌生活质量问卷13项(QLQ-LC13)和欧洲生活质量5维度-5水平(eq - 5d - 5l)问卷,在SBRT后的第一次就诊、1个月、3个月和每3个月评估患者报告的结果。关键的探索性HRQoL终点(对所有在SBRT后至少一个时间点完成QLQ-C30的患者进行分析)是QLQ-C30总体健康状况(GHS)/生活质量(QoL)评分和呼吸困难恶化(患者报告的肺毒性)的基线到早期变化(1个月至3个月)和基线到晚期变化(6个月至12个月)。探索性分析基线HRQoL、患者和sbrt相关特征(包括基于PET灌注的功能参数)对HRQoL较基线变化的影响,采用单变量分析。结果:60例患者中,早发性39例,晚发性22例。13例(33%)和7例(32%)患者生活质量恶化。在单因素分析中,心脏最大剂量、肺功能体积剂量和肺功能试验参数与HRQoL的早期恶化显著相关。只有对功能肺体积的剂量与HRQoL的晚期恶化显著相关。结论:在我们的研究中,与解剖肺参数不同,功能肺容积PET基础剂量参数的增加与HRQoL的降低有显著相关。灌注PET/CT引导下的功能性肺回避规划可能是改善肺SBRT患者HRQoL的一种简单、无创的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Radiation Oncology
Radiation Oncology ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
6.50
自引率
2.80%
发文量
181
审稿时长
3-6 weeks
期刊介绍: Radiation Oncology encompasses all aspects of research that impacts on the treatment of cancer using radiation. It publishes findings in molecular and cellular radiation biology, radiation physics, radiation technology, and clinical oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信